Next-Gen MS: Feed-forward PRO Data for MS Research
Next-Gen MS: A Prospective, Cluster-randomized Study Evaluating the Impact of "Feed-forward" Patient Reported Outcomes Data to Clinical Teams Managing Adults Living With MS in a Learning Health System for MS Research
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: US Medical Information
- Phone Number: 888-275-7376
- Email: eMediUSA@emdserono.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Alabama Neurology Associates
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20057
- Georgetown University
-
-
Georgia
-
Atlanta, Georgia, United States, 30327
- Atlanta Neuroscience Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Michigan
-
Owosso, Michigan, United States, 48867
- The Memorial Hospital, d.b.a Memorial Healthcare
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma Medical Research Foundation
-
-
Texas
-
Austin, Texas, United States, 78759
- The University of Texas of Austin
-
San Antonio, Texas, United States, 78229
- The University of Texas Health Science Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants willing and able to provide written informed consent
- Participants with clinical diagnosis of Multiple Sclerosis (MS)
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Feed-forward PRO
Participants in this group will participate in monthly learning collaborative webinars.
Feed-forward of patient reported outcomes (PRO) data collected from the main study (NCT04735406) will be used.
|
|
Control Group (Usual Care)
Participants in the control group will receive usual care practices during the clinical encounters.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline in Health-Related Quality of Life 14 Item (HR-QoL-14)
Time Frame: Baseline up to 18 Months
|
Baseline up to 18 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participants with >=1-point Increase from Baseline in Patient Determined Disease Steps (PDDS) Sustained Via Consecutive Measures Over 3 Months
Time Frame: Baseline up to 18 Months
|
Baseline up to 18 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical Responsible, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MS200077_0013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.